

FOR IMMEDIATE RELEASE

Amsterdam, Netherlands, 24 June 2013

UbiQ and Neuroscience Campus Amsterdam join forces to develop treatments for Parkinson's disease and other neurodegenerative illnesses

The brains of patients with Alzheimer's disease and other dementias, as well as Parkinson's disease, accumulate toxic proteins normally degraded by the Ubiquitin Proteasome System (UPS). Stoking UPS to clear these proteins is a leading strategy in the development of aggressive treatment for these devastating illnesses. Neuroscience Campus Amsterdam, working with Amsterdam-based UPS drug discovery specialist UbiQ, wants these treatments to reach the patients who desperately need them.

"This collaboration is perfect for both parties," said Arjen Brussaard, Scientific Director of Neuroscience Campus Amsterdam. "UbiQ has broad capabilities in understanding and modulating UPS biology, with compounds developed from an active discovery program. Neuroscience Campus Amsterdam provides insight into brain disease pathology and UPS activation measurement in human models. Together, we want to get treatments into the clinic."

"UbiQ strongly believes that UPS provides similar potential for drug targets as kinase inhibition has over the past several decades," said Alfred Nijkerk, CEO of UbiQ. "Being a spinoff of the Netherlands Cancer Institute, our main disease focuses have been outside of neurological illness. Neuroscience Campus Amsterdam allows us to work in this discovery area where patients have such substantial need."

The terms of the collaboration were not announced.

About Neuroscience Campus Amsterdam and its Industry Alliance Office

At Neuroscience Campus Amsterdam, we care about the brains of our students, research investigators, and clinicians. Most of all, we care about the brains of our patients, young and old, who suffer from chronic devastating brain disorders which reduce the quality of their lives and the lives of those around them. Neuroscience Campus Amsterdam spans VU University and Medical Center, bringing together 600+ researchers and clinicians to understand and treat the brain. Through its Industry Alliance Office, Neuroscience Campus Amsterdam develops creative and meaningful partnerships, enabling more impactful research on brain diseases and bringing the results of this research into the clinic.

About UbiQ

UbiQ is founded by dynamic young researchers in the UPS field. Improper UPS function is increasingly identified in a broad range of diseases, and cellular targets within UPS have attracted intense interest in neurodegenerative diseases such as Parkinson's disease, where toxic aggregations protein cause the death of neurons. UbiQ, spinoff of the Netherlands Cancer Institute, specializes in ubiquitin related reagents, peptides and assays. UbiQ generated some of the first commercially available custom ubiquitinated peptides and now distributes other ubiquitin related reagents worldwide. In addition to enabling drug discovery in the rapidly expanding Ubiquitin field, UbiQ is also actively developing a portfolio of proteasomal activators which can be applied in specific disease indications through partnerships with leading academic institutions and companies.

Contacts

Neuroscience Campus Amsterdam
Arjen Brussaard, Scientific Director
Phone +31 20 598 7098
arjen.brussaard@vu.nl

UbiQ Bio BV
Alfred Nijkerk, CEO
Phone: +31 6 5512 8387
alfrednijkerk@ubiqbio.com